Cheers @imback ... downramper and uprampers are equally bad but they are both entitled to express opinion.
I agree with you it is sad that an underlying agenda for downramping *may* be the hope that a drug developement fails. Well، fortunatey their hope and expression of it here has no bearing on the actually progress of the development! So, that makes it easy to either ignore them or sift through (my appraoch) and analyse what they have to say. In my some 30 years of trading i have mentally (and categorically) blocked what I "thought" was downramping and i paid heafty price by seeing things rosey! Just my own experience. But like you said lets leave it there, and move moore important and MBS forum specific discussion ..
What evidence do we have that FDA's reviwed devision was based on change or update in their procedure/process, or was it based on MSB providing more (convincing) data/response?
MSB Price at posting:
$1.10 Sentiment: Buy Disclosure: Held
(20min delay)